ABSTRACT
Objective To investigate the safety and efficacy of enteral nutrition in critically ill children with hyperpancreorrhea including hyperamylasemia and hyperlipasemia in order to provide the rationale of nutritional support for such critically ill children. Methods A total of 90 critically ill children with hyperpancreorrhea admitted in pediatric intensive care unit were enrolled for prospective study in a period from January 2014 to December 2015. The patients were randomly(random number) divided into fasting group (n=30), and in those with fasting time exceeded three days, intravenous nutrition was given; ordinary milk group (n=30) and special milk group (n=30) and in this group, those with age<1 year were given AiErShu, while those with age >1 year were given small hundred peptides in addition to the basis of routine treatment. Clinical data and biochemical findings in different groups were analyzed by X2test, t test, F test or non-parametric test to evaluate the safety and efficacy of enteral nutrition in critically ill children with hyperpancreorrhea. Results (1) There were statistically significant differences in rates of nutrition support-related symptoms such as diarrhea, electrolyte imbalance, blood glucose disorder among groups (χ2=6.975,6.074,6.300,P=0.031,0.048,0.043). (2) There were statistically significant difference in rates of serum amylase or lipase levels more than upper limit on the third day among different groups (χ2=7.081, P=0.029). There was no statistically significant difference in rates of fecal elastase-1<200 μg/g 24 hours after admission, on the 3rd day and on the 7th day among different groups (P＞0.05). There was statistically significant difference in procalcitonin on the 7th day among different groups (H=6.251,P=0.044). There was statistically significant difference in oxygenation index on the 3rd day among different groups (F=3.119, P=0.049). There was statistically significant difference in lactate on the 7th day among different groups (F=6.449,P=0.040). There was statistically significant differences in albumin on the 3rd day and on the 7th among different groups (F=5.451,P=0.006; H=24.861,P＜0.01). (3) There were statistically significant differences in PICU stay and hospital stay among different groups (F=3.222,3.891,P=0.045 ; 0.024). There was statistically significant difference in survival rate among different groups (χ2=6.240, P=0.044).Conclusions Early and right enteral nutrition was safe and effective for critically ill children with hyperpancreorrhea, and the special milk powder such asr AiReShu and small hundred peptides suitable for children with hyperpancreorrhea could effectively support nutrition for critically ill children with hyperpancreorrhea,improve the status of illness, promote disease recovery, shorten hospital stay and improve the prognosis.
ABSTRACT
BACKGROUND/AIMS: Recent studies reported that 1g of gabexate mesilate (GM) was effective in preventing endoscopic retrograde cholangiopancreatography (ERCP)-related pancreatic damage. The aim of this study was to evaluate the effectiveness of low dose GM for the prevention of ERCP-related pancreatic damage. METHODS: This study was performed prospectively with 102 consecutive patients (68 for the GM group, 34 for the placebo group) who were scheduled for ERCP. Infusion of GM (500 mg) was started 30 minutes before ERCP and continued for 12 hours afterward. The serum amylase and lipase were measured before ERCP and 4, 8, and 24 houps after ERCP. RESULTS: The incidence of hyperenzymemia was 45.6% in the GM group and 55.9% in the control group (p=0.40). Acute pancreatitis was developed in only one patient who was given the placebo. Although difficult cannulation, visualization of the pancreatic duct, performance of therapeutic procedures, and longer total procedure time were associated with an increased incidence of hyperenzymemia, the incidence of pancreatic damage was not affected by the GM treatment in these conditions. CONCLUSIONS: Prophylactic treatment with 500 mg of GM has no advantage for the prevention of ERCP-related pancreatic damage. Considering the cost effectiveness, further studies are necessary to identify the patients at greatest risk fot acute pancreatitis.